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Low Frequency Of Regulatory B-Cells And Increased
CD4+ and CD8+ Interferon-γ-producing cells in patients
with tropical spastic paraparesis associated with human
T-cell lymphotropic virus type
Yulieth Cristina Bermúdez Burbano[1]*, Angie Vanessa Caicedo Paz[1]*,
Cristhian Camilo Rivera Caldon[1], Juan Sebastián Rodríguez Constain[1],
Gloria Inés Ávila Gonzáles[1], Julio César Klínger Hernández[1],
Nancy Marin-Agudelo[2], Rosa Amalia Dueñas-Cuellar[1]
and Victoria Eugenia Niño Castaño[1]
[1]. Immunology and Infectious Diseases Research Group, Department of Pathology, University of Cauca, Cauca, Colombia.
[2]. Postdoctoral Research Associate, Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO., USA.

Abstract
Introduction: Tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) is a disease caused by human T-cell
lymphotropic virus type 1 (HTLV-I) that mainly infects CD4 T cells—for example, those of the CD4+CD25hiFOXP3+ [Treg]
phenotype—where it inhibits forkhead box protein P3 (FOXP3) expression and promotes interferon-γ (IFN-γ) expression.
However, the role it exerts on regulatory B cells (CD19+CD24hiCD38hi; Breg) is unknown. Methods: The frequencies of Treg
and Breg cells was evaluated and the Th1 profiles were assessed in TSP/HAM patients and healthy control subjects. Results:
Low percentages of Breg cells and high production of IFN-γ were observed in patients compared to those in healthy control
subjects. Conclusions: The low percentage of Breg cells in patients and the increase in the frequency of Th1 cells suggest an
imbalance in the control of the inflammatory response that contributes to the immunopathogenesis of TSP/HAM.
Keywords: Tropical Spastic Paraparesis. HTLV-1 virus. Regulatory T cells. Regulatory B cells. Interferon-γ.
INTRODUCTION
Human T-cell lymphotropic virus type 1 (HTLV-1) was
the first human retrovirus with oncogenic properties to be
described1. It affects 5–10 million people worldwide, especially
endemic regions such as Africa, Japan, the Caribbean, Iran,
Australia, Peru, Chile, Brazil, and Colombia2. The incubation
period of the virus ranges from years to decades and its
transmission occurs through sexual contact, blood transfusions,
needle sharing, and from mother to child through breast milk3.
The virus is considered the causative agent of two potentially
deadly diseases; namely, adult T-cell leukemia/lymphoma (ATL
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or ATLL) and tropical spastic paraparesis/HTLV-1 associated
myelopathy (TSP/HAM). However, not all infected people
develop these disorders; while an estimated 2–5% develop
ATL and 0.25–2% develop TSP/HAM, the rest remain as
asymptomatic carriers for the rest of their lives4.
In Colombia, the virus was first described in 1981 in the
region of Tumaco (Nariño), with an estimated prevalence of
7.5–10% in the Pacific Coastal Areas5. However, the virus is
distributed to non-coastal areas such as Antioquia, Risaralda,
Córdoba and Cundinamarca, among others. Between 2010 and
2014, seven cases of HTLV-1 were reported in the regions of
Nariño, Putumayo, Valle del Cauca, Risaralda and the Caribbean
coast6. Despite the data shown above, epidemiological studies of
the virus have not been carried out, which has limited knowledge
of its prevalence in Colombia.
TSP/HAM is characterized by an upper motor neuron
lesion and a slow and progressive axon-myelin degeneration
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in the anterolateral cords of the thoracic and/or lumbar spinal
cord. The associated clinical manifestations include decreased
strength and spasticity in unilateral or bilateral lower limbs,
back pain, and urinary symptoms (nocturia, increased in urinary
frequency, incontinence, and erectile dysfunction). In addition,
Patellar hyperreflexia with or without clonus and Babinski sign
or substitutes may occur, with less sensory involvement and
without affecting the upper limb or cognitive functions. This
weakness increases progressively, and in most cases, there is
a spastic or scissor gait, which can evolve to compromise the
ability to walk3.
The events that trigger the development of TSP/HAM are
not clearly known. Nevertheless, its development is associated
with deficiencies in the immunoregulatory process. The virus
infects CD4+CD25hiFOXP3+ Treg cells, activates the Tax viral
protein, inhibits forkhead box protein P3 (FOXP3) expression,
and promotes interferon gamma (IFN-γ) expression7. Therefore,
infected cells acquire a Th1 type phenotype, becoming IFN-γ
producing cells able to cross the blood-brain barrier and enter
the central nervous system (CNS)8. The inflammatory response
in the CNS is represented by TCD4+ cells, high production of
IFN-γ, and TCD8+ cell recruitment specifically against the virus9.
Regulatory B-cells represent a subtype of cells that, like Treg
cells, can inhibit the inflammatory response during infections
and inflammation; however, they are altered in number and
function during autoimmune diseases. B-cells with regulatory
capacity have been described, with CD19 +CD24hiCD38hi,
CD19+CD24hiCD27+, and CD19+CD25hiCD71hi phenotypes
found in blood and in sites of inflammation10. Breg cells with
a CD19+CD24hiCD38hi phenotype inhibit Th1 differentiation
in vitro 11. They also inhibit the inflammatory response
through mechanisms dependent on interleukin (IL)-10, IL35, and transforming growth factor beta (TGF-β), capable of
controlling the induction and functioning of the Treg cells.
In other autoimmune pathologies such as multiple sclerosis
and rheumatoid arthritis, a deficiency in CD19+CD24hiCD38hi
Breg cells has been observed, which leads to low production
of IL-10 and deficiency in the control of Th1 differentiation12.
However, the contribution of regulatory B-cells (BregCD19+CD24hiCD38hi) in the pathogenesis of TSP/HAM has
not yet been described.
Therefore, this work aimed to evaluate the frequency
of circulating regulatory B-cells and their relationship
to the frequency of TCD4+ and TCD8+ IFN-γ-producing
cells in patients with TSP/HAM to provide information on
immunoregulation mechanisms mediated by Breg cells in the
pathogenesis of this disease.
METHODS
Study population
Nineteen patients over 18 years of age from the Neurology
Service at San José University Hospital in Popayán, CaucaColombia were studied. The included participants had
neurological symptoms suspicious of TSP/HAM according
to the treating neurologist, including spastic paraparesis, gait
alterations, paresthesia, alterations in sensitivity, sensation
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of muscular weakness, and urinary incontinence, as well
as hyperreflexia in the lower limbs, muscular hypertonia/
hypotonia and positive Babinski sign. These individuals
underwent serology and western blot for HTLV-1, nine of which
had positive findings and were selected for study inclusion.
Additionally, nine healthy control subjects negative for HTLV-1
by serology, human immunodeficiency virus (HIV)-negative
and without acute or chronic conditions were included and were
matched to patients according to age and sex.
Ethical considerations
Each participant signed informed consent forms and
completed a survey containing information on sociodemographic
and neurological clinical data prior to providing a peripheral
venous blood sample. All procedures were approved by the
Ethics Committee of the University of Cauca.
Peripheral venous blood sampling
Peripheral blood sampling was performed by venous
puncture in the forearm following biosafety protocols. This
procedure was performed by trained personnel. Approximately
15 mL of peripheral blood was taken from each participant
in tubes with and without additives (Vacutainer, BecktonDickinson, USA).
Detection of HTLV-1 virus infection
Enzyme-linked immunosorbent assays (ELISAs) were
performed from the serum sample to detect the presence of
anti-HTLV-1 antibodies, according to the manufacturer's
recommendations (DIA.PRO, Milan, Italy). In positive samples,
the diagnosis was confirmed by Western blot, according to the
manufacturer's recommendations (Bio-Rad, Berkeley, CA).
Extraction of mononuclear cells from peripheral blood
Peripheral blood mononuclear cells (PBMC) were separated
by density gradient centrifugation with Ficoll-Hypaque
(BioWhittaker, Walkersville, MD). Cell viability was evaluated
using Trypan blue dye (Sigma Immunochemicals, St. Louis,
MO, USA).
Phenotyping of Treg and Breg cell subpopulations
Approximately 1x106 PBMC were deposited into flow
cytometry tubes (Falcon, Becton Dickinson, Oxnard,
California). To identify Treg cells, surface labeling was
performed with anti-CD4- fluorescein isothiocyanate (FITC)
(clone: OKT4, eBioscience, San Diego, CA) and anti-CD25PECy5 (clone: BC96 eBioscience) antibodies. The cells were
fixed with 2% paraformaldehyde, permeabilized with the
fixation/permeabilization buffer solution (eBioscience, San
Diego, CA) according to the manufacturer's recommendations,
and subsequently incubated with anti-FOXP3-PE antibody
(clone: 259D Biolegend). Finally, the cells were washed and
resuspended in phosphate-buffered saline (PBS) and read
on an Accuri C6 flow cytometer (BD Biosciences). For the
phenotyping of the Breg cells, anti-CD19-PE (Beckman Coulter,
Brea, CA, USA), anti-CD24-Alexa-fluor-647 (clone: ML5
BioLegend) and anti-CD38-PECy5 (clone: HIT2 BioLegend)
antibodies were added for 30 minutes at room temperature.
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Subsequently, the cells were washed with PBS and fixed with 2%
paraformaldehyde. The samples were read in a flow cytometer.
Evaluation of the intracellular production of IFN-γ
For the detection of intracellular IFN-γ, 1x106 PBMC were
stimulated with phorbol myristate acetate (PMA) (40 ng/mL)
(InvivoGen, San Diego, CA, USA) and ionomycin (1 μg/mL)
(Sigma, St. Louis, MO, USA) in the presence of 10 μg/mL
Brefeldin A (Sigma, St. Louis, MO, USA) for six hours at 37°C
and 5% CO2. At the end of the incubation period, the cells were
labeled with anti-CD4-PECy5 (clone: RPA-T4) and anti-CD8PECy5 (clone: RPA-T8, BioLegend) antibodies for 30 minutes
at room temperature, then washed with PBS and fixed with 2%
paraformaldehyde. The cells were permeabilized with fixation/
permeabilization buffer solution (eBioscience, San Diego, CA)
according to the manufacturer's recommendations and incubated
with anti-IFN-γ -FITC antibody (clone 4S.B3, eBioscience) for 1.5
hours at 4°C under darkness. Finally, the cells were washed with PBS
and analyzed on an Accuri C6 flow cytometer (BD Biosciences).
Statistical analysis
The sociodemographic variables and clinical characteristics
of the patients were analyzed by measures of central tendency
and dispersion. The frequencies of Treg, Breg, and IFN-γ
producing T-cells in the peripheral blood of TSP/HAM patients
and control subjects were compared by Mann–Whitney U tests.
The statistical analysis was performed in GraphPad Prism
Software 5 (San Diego, CA, USA).
RESULTS
Socio-demographic and clinical characteristics
Among the nine confirmed patients with TSP/HAM, 55.6%
were men and 44.4% were women, with ages ranging from
32–79 years (median: 58.8 years), mainly from the rural area
of the Department of Cauca (55.6%). As an epidemiological
antecedent of the risk of acquiring HTLV-1 infection, six
patients (75%) had received blood transfusion at least once in
their lifetimes and none had been intravenous drug users or had
had homosexual relationships prior to the study. According to
the neurological clinical examinations, the most frequent signs
and symptoms were paraparesis of the lower limbs, paresthesia,
gait alterations and hypotonia, which were present in 55.6% of
the cases. Babinski sign and hyperreflexia in the lower limbs
were present in 66.6% of the cases. Urological symptoms such
as urinary incontinence and erectile dysfunction occurred in
88.8% of patients (Table 1).
Percentage of CD4+CD25hi and CD4+CD25hiFOXP3+ cells
in TSP/HAM patients and control subjects
Cells with a regulatory function capable of suppressing
the inflammatory response are altered in number and function
in different chronic inflammatory and autoimmune diseases.
These cells are identified by the high expression of CD25 in
addition to the expression of the FOXP3 transcription factor13,
which is considered the best lineage marker in this cellular
subpopulation. In the present study, the frequencies of cells

with CD4+CD25hi and CD4+CD25hiFOXP3+ phenotypes in
peripheral blood of TSP/HAM patients and control subjects were
evaluated by flow cytometry. The analysis of the frequencies
of these subpopulations showed no significant differences
between TSP/HAM patients and control subjects, although an
increasing tendency of these two subpopulations was observed
in the patient group. The median percentages of CD4+CD25hi
cells in the patients and control groups were 2.3 (interquartile
range [IQR] 1.25–5.1) and 1.58 (IQR 1.06-2.5), respectively. In
contrast, the percentages of CD4+CD25hiFOXP3+ cells were 3.38
(IQR 2.26–3.48) and 2.5 (1.52–3.44), respectively (Figure 1).
Percentages of Breg cells (CD19+CD24hiCD38hi) in TSP/
HAM patients and control subjects
Under normal conditions, Breg cells are characterized by their
inhibition of the inflammatory response; however, the number
of these cells is altered in autoimmune diseases. In this study,
the median percentage of Breg cells with CD19+CD24hiCD38hi
phenotype was significantly lower in patients with TSP/HAM
compared to that in the control subjects (2.9 [IQR1.9–2.4] vs.
8.5 [IQR 4.4–11.2], p <0.05) (Figure 2). This result suggests
that within this pathology there are alterations in the number
of Breg cells (CD19+CD24 hiCD38 hi) which contribute to the
control deficiency of the inflammatory response of the disease.
Percentages of CD4+ and CD8+ IFN-γ producing cells in
TSP/HAM patients and control subjects
Previous studies have shown an increase in the frequency
of IFN-γ producing cells in TSP/HAM patients7. In the present
study, quantification the percentages of CD4+ and CD8+ IFN-γ
-producing cells showed an increased percentage in patients
compared to that in the control subjects (p<0.01). The median
percentages of T CD4+IFN-γ+ T cells in the patients and
controls were 9.7% (IQR 2.9–23.7) and 0.78% (IQR 0.28–4.1),
respectively. Similar results were observed for CD8+IFN-γ+ T
cells, with medians of 16.1% (IQR 4.9–47.3) and 1.6% (IQR
1.5–8.04), respectively (p <0.05) (Figure 3).
Ratios of the percentages of CD4+IFN-γ +/
CD19+CD24hiCD38hi and CD8+IFN-γ +/
CD19+CD24hiCD38hi cells in TSP/HAM
patients and control subjects
Considering the low percentages of Breg cells (CD19+CD24hi
CD38hi) and high percentages of CD4+ and CD8+ IFN-γ producing
cells TSP/HAM patients, the coefficient of the ratio of CD4+IFN-γ+/
CD19+CD24hiCD38hi and CD8+IFN-γ+/CD19+CD24hi CD38hi
cells was calculated between patients and control subjects. The
coefficient was higher in patients than that in control subjects for
the ratio of CD4+IFN-γ+/CD19+CD24hi CD38hi, (median: [IQR]
2.7 [0.9–11.2] in patients vs median: [IQR] 0.07 [0.03–1.1] in
control subjects; p <0.05) and for the ratio of CD8+IFN-γ +/
CD19+CD24hi CD38hi, (median: [IQR] 5.2 [1.4–18.7]) in patients
vs median: [IQR] 0.28 [0.13–1.2] in control subjects; p <0.01)
(Figure 4). This inverse relationship suggests an expansion of
IFN-γ producing cells and a reduction in the number of Breg
cells (CD19+CD24hiCD38hi) in TSP/HAM.
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TABLE 1: Sociodemographic and clinical characteristics of patients with tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) and in
control subjects.
TSP/HAM

Control subjects

(n=9) n (%)

(n=9) n (%)

Male

5 (55.6)

5 (55.6)

Female

4 (44.4)

4 (44.4))

58.8 (32-79)

57.6(31-78)

Urban

4(44.4)

8(88.8)

Rural

5 (55.6)

1 (11.1)

Normal

6 (66.7)

4 (44.4)

Overweight

3(33.3)

5(55.5)

Breastfeeding background

4(44.4)

8 (88.8)

Blood donation background

3(33.3)

4 (44.4)

Transfusion background

6 (75)

0(0)

Median age (range)
Residence

* BMI (kg/m )
2

Neurological symptoms

Urological symptoms

LL spastic paraparesia

5 (55.6)

LlLparesthesia **

5 (55.6)

Gait alterations

5 (55.6)

Babinski sign

6 (66.6)

LL normotonia

2 (22.2)

LL hypertonia

1 (11.1)

LL hypotonia

5 (55.6)

LL hyporeflexia

1 (11.1)

LL hypereflexia with or without clonus

6 (66.6)

Cerebellar signs

2 (22.2)

Alterations of cranial pairs

1 (11.1)

Incontinence

5 (55.6)

Erectile dysfunction

3 (33.3)

*BMI: body mass index; **LL: lower limbs. Obesity and low weight were examined in patients and control subjects in cases in which no patient with these
characteristics was found.

DISCUSSION
The present work evaluated the percentages of Treg
(CD4+CD25hi and CD4+CD25hiFOXP3+), Breg (CD19+CD24hi
CD38hi), and CD4 and CD8 IFN-γ -producing cells in nine patients
with TSP/HAM, compared to those in healthy control subjects.
Regarding sociodemographic data, the presentation of the
disease at older ages (median age 58.8 years) could be associated
with the natural evolution of the virus and the chronicity of
infection that is consistent with what has been reported in other
studies14-16. Intravenous drug use, homosexual relations, and
blood transfusions have been described as epidemiological
risk factors for acquiring HTLV-1 infection. From these, only
a background history of blood transfusions was present among
the patients and could have been the main route of transmission
in these cases.
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TSP/HAM patients with neurological characteristics typical
of the disease associated with HTLV-1 infection initially present
sensory/motor manifestations (hyperreflexia, hypertonia),
urological manifestations (urinary incontinence, sexual
dysfunction, neurogenic bladder), which evolve to progressive
spastic paraparesis in the lower limbs, gait alterations, and
generalized pyramidal signs (Babinski sign and substitutes,
Hoffman's sign)17,18. In our study, there was a greater tendency
for patients to develop this type of symptomatology. These
findings correlate with prior reports in the literature in which
patellar hyperreflexia and Babinski sign may be present in
100% and 90–100% of patients infected with the virus18,19. The
other frequent symptoms in this group of patients included
urological symptoms, reaffirming the importance of looking
for this symptomatology in all patients in whom infection with
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FIGURE 1: Quantification of the frequency of circulating Treg cells. Representative graph showing the flow cytometry analysis strategy for CD4+CD25hi
and CD4+CD25hiFOXP3+cellular subpopulations (A). Dot graphs showing the frequency of CD4+CD25hi cells (B) and CD4+CD25hiFOXP3+ cells (C) in nine
TSP/HAM patients and nine healthy control subjects. Each dot represents individual values in each group, while the horizontal lines indicate the median
and standard errors. The data were analyzed using Mann–Whitney U tests. p = ns.

FIGURE 2: Quantification and percentage of Breg cells with CD19+CD24hiCD38hi phenotype in peripheral blood
mononuclear cells. A representative flow cytometry graph of B cells (CD19+) corresponding to the CD19+CD24hiCD38hi
subpopulations (A). The dot chart shows the frequency of Breg cells (CD19+CD24hiCD38hi) in nine TSP/HAM patients
and control subjects. Each dot represents individual values in each group, while the horizontal lines indicate the
median and standard errors. The data were analyzed using Mann–Whitney U tests. ** = p <0.01.
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FIGURE 3: Quantification of the frequency of CD4+ and CD8+ lymphocytes producing interferon-gamma (IFN-γ). Representative flow
cytometry graph of T CD4+ (A) and CD8+ (B) subpopulations of IFN-γ producing cells. The dot charts show the frequency of CD4+ (C) and CD8+
(D) IFN-γ producing cells in nine TSP/HAM patients and nine healthy control subjects. Each dot represents an individual value in each group, while
the horizontal lines indicate the median and standard errors. The data were analyzed using Mann–Whitney U tests. ** = p <0.01, * = p <0.05.

FIGURE 4: Percentage ratios of CD4+IFN-γ+/CD19+CD24hiCD38hi (A) and CD8+IFN-γ+/CD19+CD24hiCD38hi (B) cells in nine patients
with TSP/HAM and nine healthy control subjects. Each dot represents an individual value in each group, while the horizontal lines indicate
the median and standard errors. The data were analyzed using Mann–Whitney U tests with p <0.05 (*) and p <0.01 (**).
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HTLV-1 is suspected, or in those patients who consult for urinary
symptoms with an unclear origin. This is important given that
these types of alterations can become a silent problem and occur
many years before the manifestation of the spastic paraparesis
associated with HTLV-120. It is noteworthy that of the 19 patients
suspected of TSP/HAM, only nine received confirmation of
the disease, reaffirming the similarity between the clinical
presentation of TSP/HAM and a variety of neurological diseases,
especially those associated with motor neuron disorders.
Therefore, according to each patient’s clinical context, a call is
made to consider HTLV-1 infection as an alternative diagnosis
when other, more common diseases have been ruled out since
this diagnosis could alter the patient prognosis and management.
Evaluation of the cells with regulatory function in the nine
patients with TSP/HAM showed no significant difference in Treg
cell populations with CD4+CD25hi and CD4+CD25hiFOXP3+
phenotypes from those in the control subjects. These results
were discordant with those reported in the literature showing
decreased expression of FOXP3-positive cells in patients with
TSP/HAM7,21,22. This difference could be due to the fact that
CD4+CD25hiFOXP3+ cells were quantified in this study from the
total number of mononuclear cells isolated from patients and
control subjects, without discriminating if they were infected,
which leads us to suspect that the virus affects the expression of
FOXP3 directly in infected cells, without directly or indirectly
altering uninfected cells of the same phenotype.
Alterations in the number and function of Breg cells
have been described in other chronic inflammatory and
autoimmune diseases. To our knowledge, the present study is
the first to describe the frequency of circulating Breg cells with
CD19+CD24hiCD38hi phenotype in TSP/HAM pathology. The
reduced frequency of these cells in TSP/HAM patients compared
to those in healthy control subjects is similar to the results
reported for this cell lineage in other autoimmune inflammatory
pathologies such as systemic lupus erythematosus 11 and
multiple sclerosis23. The reduction of Breg cells in patients with
TSP/HAM could be associated with defects in the regulation
of Th1 type cells, which has been demonstrated to trigger
a physiological process which results in tissue damage
caused mainly by an increase in proinflammatory cytokines
such as IFN-γ7.
Evaluation of the production of IFN-γ in TCD4+ and TCD8+
lymphocytes in patients and healthy control subjects showed
a significant increase in patients; consistent with that reported
in the literature showing IFN-γ-producing cells proliferation
by impairment of Treg cells to regulate Th1 cell differentiation
in TSP/HAM21. Other phenomena that explain Th1 expansion
include a cellular plasticity phenomenon described in 2017
by Yamano and Coler-Reilly, who demonstrated reduced
expression of regulatory T-cells with CD4+CD25hiFOXP3+
phenotype infected by HTLV-1 as a consequence of viral Tax
protein activation. This protein activates the expression of the
transcription factor T-bet, whose main function is to decrease
the expression of FOXP3 and to increase IFN-γ production,
resulting in cellular plasticity in which the cells are converted
to a Th1-like phenotype23,24.

Since a high production of IFN-γ in CD4+ and CD8+ cells
and a low percentage of Breg cells (CD19+CD24hiCD38hi)
were observed in patients with TSP/HAM, we compared the
percentage ratio of CD4+IFN-γ and CD8+IFN-γ cells to the
percentage of Breg cells. The results showed a significant
difference in both cases. Thus, the coefficient of the relationship
between IFN-γ-producing and Breg cells was higher in
patients with TSP/HAM compared to that in healthy control
subjects. Therefore, patients with TSP/HAM had a greater
number of IFN-γ-producing cells while the number of Breg
cells decreased, which could be associated with defects in the
regulation of Th1-type cells and may be related to inflammatory
processes mediated by IFN-γ, which in turn mediates tissue
damage.
To our knowledge, the present study is the first to
demonstrate the role of Breg cells (CD19+CD24hiCD38hi)
in the pathophysiology of TSP/HAM. The decrease of this
cellular phenotype in the pathology is related to the deficiency
of the regulatory processes of the immune system, which,
combined with the effect exerted by the virus on Treg cells,
triggers a predominance of Th1 cells, which is associated with
characteristic tissue damage. As there are currently no accurate
treatment for HTLV-1 infection nor TSP/HAM, the present
results offer another perspective in the search for new targets;
more specifically, for the application of innovative treatments
focused on the phenotypes described to improve the immune
regulatory process and prevent tissue damage associated with
TSP/HAM.
One of the limitations of the study was the small number of
patients evaluated; despite this, considering the low prevalence
of the disease and the difficulty in clearly identifying patients
infected with the virus, the results presented here contribute
significantly to the study of the immunopathogenesis of the
disease. Additionally, future studies that directly evaluate the
function of regulatory cells in infected cells would complement
the data presented here.
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